echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xianju Pharmaceutical's Mifepristone Tablets Received Consistency Evaluation Acceptance Notice

    Xianju Pharmaceutical's Mifepristone Tablets Received Consistency Evaluation Acceptance Notice

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 15, Xianju Pharmaceutical issued an announcement stating that the company had recently received a notice of acceptance of the consistency evaluation of mifepristone tablets issued by the National Medical Products Administration for the termination of intrauterine pregnancy and emergency contraception


    The approval document numbers of Xianju Pharmaceutical 25mg Mifepristone Tablets are: National Medicine Standard H10950347, National Medicine Standard H20000649


    Mifepristone is an anti-progestin at the level of progesterone receptors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.